186 related articles for article (PubMed ID: 34130291)
1. Calcineurin Inhibitor Toxicity in Solid Organ Transplantation.
Karolin A; Genitsch V; Sidler D
Pharmacology; 2021; 106(7-8):347-355. PubMed ID: 34130291
[TBL] [Abstract][Full Text] [Related]
2. The safety of calcineurin inhibitors for kidney-transplant patients.
Malvezzi P; Rostaing L
Expert Opin Drug Saf; 2015 Oct; 14(10):1531-46. PubMed ID: 26329325
[TBL] [Abstract][Full Text] [Related]
3. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
4. Calcineurin inhibitor sparing in paediatric solid organ transplantation : managing the efficacy/toxicity conundrum.
Tredger JM; Brown NW; Dhawan A
Drugs; 2008; 68(10):1385-414. PubMed ID: 18578558
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers for individualized dosage adjustments in immunosuppressive therapy using calcineurin inhibitors after organ transplantation.
Fu R; Tajima S; Suetsugu K; Watanabe H; Egashira N; Masuda S
Acta Pharmacol Sin; 2019 Feb; 40(2):151-159. PubMed ID: 29950613
[TBL] [Abstract][Full Text] [Related]
6. Safety of mTOR inhibitors in adult solid organ transplantation.
Ventura-Aguiar P; Campistol JM; Diekmann F
Expert Opin Drug Saf; 2016; 15(3):303-19. PubMed ID: 26667069
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ketoconazole combined with calmodulin inhibitor in solid organ transplantation: A systematic review and meta-analysis.
Xue T; Yang T; Chen C; Wu S; Li M; Ma L; Zhou Y; Cui Y
J Clin Pharm Ther; 2020 Feb; 45(1):29-34. PubMed ID: 31571253
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
Hüsing A; Schmidt M; Beckebaum S; Cicinnati VR; Koch R; Thölking G; Stella J; Heinzow H; Schmidt HH; Kabar I
Ann Transplant; 2015 Nov; 20():707-13. PubMed ID: 26608590
[TBL] [Abstract][Full Text] [Related]
9. The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trial.
Sommerer C; Schaier M; Morath C; Schwenger V; Rauch G; Giese T; Zeier M
Trials; 2014 Dec; 15():489. PubMed ID: 25494823
[TBL] [Abstract][Full Text] [Related]
10. Pathophysiological mechanisms of calcineurin inhibitor-induced nephrotoxicity and arterial hypertension.
Hošková L; Málek I; Kopkan L; Kautzner J
Physiol Res; 2017 May; 66(2):167-180. PubMed ID: 27982677
[TBL] [Abstract][Full Text] [Related]
11. The Many Faces of Calcineurin Inhibitor Toxicity-What the FK?
Farouk SS; Rein JL
Adv Chronic Kidney Dis; 2020 Jan; 27(1):56-66. PubMed ID: 32147003
[TBL] [Abstract][Full Text] [Related]
12. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation.
de Jonge H; Naesens M; Kuypers DR
Ther Drug Monit; 2009 Aug; 31(4):416-35. PubMed ID: 19536049
[TBL] [Abstract][Full Text] [Related]
13. Calcineurin inhibitors and nephrotoxicity in children.
Liu F; Mao JH
World J Pediatr; 2018 Apr; 14(2):121-126. PubMed ID: 29532435
[TBL] [Abstract][Full Text] [Related]
14. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
Rivelli RF; Gonçalves RT; Leite M; Santos MA; Delgado AG; Cardoso LR; Takiya CM
Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Hypertension Because of Immunosuppressive Therapy After Solid Organ Transplantation-Pharmacological Approach.
Gilewski W; Banach J; Rogowicz D; Wołowiec Ł; Sielski S; Grześk G
J Cardiovasc Pharmacol; 2021 Jun; 77(6):735-744. PubMed ID: 34001720
[TBL] [Abstract][Full Text] [Related]
16. Drug interactions between direct-acting oral anticoagulants and calcineurin inhibitors during solid organ transplantation: considerations for therapy.
Lam E; Bashir B; Chaballa M; Kraft WK
Expert Rev Clin Pharmacol; 2019 Aug; 12(8):781-790. PubMed ID: 31242782
[No Abstract] [Full Text] [Related]
17. Nuclear Factor of Activated T Cells-Regulated Gene Expression as Predictive Biomarker of Personal Response to Calcineurin Inhibitors.
Sommerer C; Giese T
Ther Drug Monit; 2016 Apr; 38 Suppl 1():S50-6. PubMed ID: 26418701
[TBL] [Abstract][Full Text] [Related]
18. Calcineurin inhibitors in kidney transplantation: friend or foe?
Casey MJ; Meier-Kriesche HU
Curr Opin Nephrol Hypertens; 2011 Nov; 20(6):610-5. PubMed ID: 21885969
[TBL] [Abstract][Full Text] [Related]
19. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.
Kälble F; Schaier M; Schäfer S; Süsal C; Zeier M; Sommerer C; Morath C
Expert Opin Pharmacother; 2017 Jun; 18(8):799-807. PubMed ID: 28460546
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics in immunosuppressants: impact on dose requirement of calcineurin inhibitors in renal and liver pediatric transplant recipients.
Quteineh L; Verstuyft C
Curr Opin Organ Transplant; 2010 Oct; 15(5):601-7. PubMed ID: 20720493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
